Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib with or without fosbretabulin in recurrent ovarian cancer
ISRCTN30090285Phase 2Completed
- Sponsor
- The Christie
- Start
- Sep 2014
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of pazopanib and fosbretabulin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (5 arms), sponsored by The Christie. Primary endpoints: Dose-limiting toxicities of pazopanib and fosbretabulin combination and Progression-free survival / progressive disease by RECIST. Started Sep 2014; status: completed.
02
Drugs
pazopanibfosbretabulin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ISRCTN30090285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN30090285.